Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Pain
- Pharmaceuticals
- Personal Care Products
- Medical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27204
License Grant
The Licensor entered into an agreement with an undisclosed Licensee a director of the Company, whereby the Licensor granted the Licensee a non-exclusive right to make, import and use the Licensee's product, Esterom®, under the Licensor's licensed patents and to use the Licensee's confidential information to develop new products that contain the same active ingredients as Esterom®, but are formulated differently.
License Property
Esterom is an investigational drug being studied as a topical analgesic. Chemically, it is a mixture of compounds derived from the esterification of cocaine in propylene glycol.
Field of Use
Esterom®, a topically applied compound for the treatment of impaired range of motion associated with acute lower back sprain and acute painful shoulder.
IPSCIO Record ID: 27241
License Grant
We agreed to pay a royalty in connection with our acquisition of the rights to the three original patents for Esterom® solution. Esterom® solution, a topical formulation for the treatment of conditions involving impaired range of motion. Impaired range of motion often accompanies injuries and disorders of the shoulder and lower back, as well as other conditions of the joints. Esterom® solution is derived from a process involving the chemical breakdown of cocaine into new and different molecules, three of which have been patented by us. We have completed four preclinical animal studies and Phase I and Phase II human clinical trials for Esterom® solution. These trials indicated that Esterom® solution was well tolerated at the dose used. The Licensor is undisclosed.
IPSCIO Record ID: 27076
License Grant
In January 1998, we granted a director of the Company a non-exclusive right for three years to develop both improved products and new products. Improved products are those that contain the same active ingredients as Esterom® solution, but that are formulated differently. New products are those which are developed from cocaine or a derivative and are separately patentable. We will have all rights to the improved and new products.
Field of Use
The rights granted apply to research and development work on Esterom and medical uses (human and animal) of cocaine.
IPSCIO Record ID: 319352
License Grant
Licensor (of the United Kindgom) granted Licensee the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing Licensor’s spray formulation technology (Licensor Product), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses).
License Property
Topical Spray Technology product mean DSF100 or EpoladermTM and OSF200, a topical nonsteroidal anti-inflammatory drug. This Technology is a therapeutic treatment for topicals and transdermal deliveries due to its adhesion and accessibility properties, especially around joints and curved body surfaces.
OSF200 – for chronic osteoarthritis of the knee
DSF100 or EpoladermTM – for acute musculoskeletal pain
The product candidate is covered by US Patent No. 8,349,297. The patents contain broad composition claims to a platform of pharmaceutical formulations which form a film on spray administration where the active agent is present at least 80% saturation and there is no undissolved active agent in the formulation. The claims also include a method of treatment and an aerosol dispenser containing the formulation.
8,349,297 – Topical formulations
Field of Use
The field of use is for the treatment of pain to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses) and not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain such as acute musculoskeletal pain and chronic osteoarthritis of the knee.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
